

PEEL HUNT

Peel Hunt LLP
Moor House
120 London Wall
EC2Y 5ET

The Independent Directors
Sinclair Pharma plc
1st Floor
Whitfield Court
30-32 Whitfield Street
London
W1T 2RQ

18 September 2018

Dear Sirs

RECOMMENDED CASH OFFER FOR SINCLAIR PHARMA PLC (“SINCLAIR”) BY HUADONG MEDICINE AESTHETICS INVESTMENT (HONGKONG) LIMITED (“HUADONG”), AN INDIRECT WHOLLY OWNED SUBSIDIARY OF HUADONG MEDICINE CO., LIMITED.

We refer to the Rule 2.7 announcement in relation to the recommended cash offer by Huadong for the entire issued and to be issued share capital of Sinclair dated on or around the date of this letter (the “Rule 2.7 Announcement”).

We hereby consent to the issue of the Rule 2.7 Announcement with the inclusion therein of our name and references to ourselves, in each case in the form and context in which they appear.

Yours faithfully



James Steel

for and on behalf of Peel Hunt LLP